Biogen Wins Patent Ruling for $4 Billion MS Treatment
- Posted by Janet Tice
- On March 30, 2017
As reported by Robert Weisman in The Boston Globe, Biogen’s patent on its top-selling multiple sclerosis treatment, Tecfidera, was upheld by a legal ruling in which the U.S. Patent Trial and Appeal Board rejected a challenge by Texas hedge fund manager Kyle Bass. Bass has been working for years to invalidate key intellectual property rights […]
Read More